Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

R&D Collaboration Targets Alzheimer's

by Michael McCoy
June 22, 2009 | A version of this story appeared in Volume 87, Issue 25

Boehringer Ingelheim will collaborate with Vitae Pharmaceuticals, a small-molecule drug discovery firm based in Fort Washington, Pa., on the R&D of beta-secretase inhibitors for the treatment of Alzheimer's disease. Under the agreement, Vitae will receive cash payments, an equity investment, and research funding totaling $42 million. The firm also will be eligible to receive $200 million in future milestone payments plus other milestone and royalty payments. In 2007, Vitae received $36.5 million in payments from BI in a collaboration aimed at diabetes and other diseases related to metabolic syndrome.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.